When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Mucosite oral

Última revisão: 1 Nov 2024
Última atualização: 12 Aug 2021

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • eritema ou ulceração da mucosa oral
  • dor oral
Detalhes completos

Outros fatores diagnósticos

  • comprometimento alimentar
  • diarreia
  • febre
Detalhes completos

Fatores de risco

  • esquemas de quimioterapia intensiva
  • radioterapia na cavidade oral
  • quimiorradiação
  • polimorfismos genéticos em enzimas metabólicas do medicamento
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • diagnóstico clínico
Detalhes completos

Investigações a serem consideradas

  • hemograma completo e diferencial
  • hemoculturas
  • esfregaço superficial da lesão para microscopia
  • cultura fúngica
  • cultura viral ou reação em cadeia da polimerase
Detalhes completos

Algoritmo de tratamento

Inicial

pacientes submetidos a transplante de células-tronco hematopoéticas: medidas preventivas

pacientes que recebem fluoruracila em bolus: medidas preventivas

pacientes que recebem radioterapia na cavidade oral: medidas preventivas

Aguda

mucosite oral estabelecida

Colaboradores

Autores

Rajesh V. Lalla, DDS, PhD, DABOM

Associate Professor

Associate Dean for Research

Section of Oral Medicine

University of Connecticut School of Dental Medicine

Farmington

CT

Declarações

RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics and Novartis.

Ourania Nicolatou-Galitis, DDS, MSc, DrDent

Professor

Hospital Dentistry

National & Kapodistrian University of Athens

Athens

Greece

Declarações

ONG has received fees from Angelini pharma to author a review article on oral mucositis. ONG is an author of several references cited in this topic.

Nikolaos Tsoukalas, MD, MSc, PhD

Medical Oncologist

Associate Director

Department of Oncology

401 General Military Hospital

Athens

Greece

Declarações

NT declares that he has no competing interests.

Agradecimentos

Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.

Declarações

EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.

Revisores

Michael Brennan, DDS, MHS

Associate Chairman and Oral Medicine Residency Director

Department of Oral Medicine

Carolinas Medical Center

Charlotte

NC

Declarações

MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.

Maria Michelagnoli, MB ChB, MD, FRCPCH

Consultant Pediatric and Adolescent Oncologist

University College London Hospitals

London

UK

Declarações

MM declares that she has no competing interests.

  • Mucosite oral images
  • Diagnósticos diferenciais

    • Candidíase oral
    • Infecção pelo vírus do herpes simples
    • Doença do enxerto contra o hospedeiro
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
    • MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal